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TRAIL-R as a Negative Regulator
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lacking a death domain and TRAIL-R3 exists as a GPI-
linked protein. These latter two receptors are thought
to function as decoy proteins that can inhibit signaling
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through TRAIL-R1 and -R2 (Ashkenazi and Dixit, 1999).and Astar Winoto1,*
The fifth receptor for TRAIL, osteoprotegerin, is a soluble1Department of Molecular and Cell Biology
protein that participates in regulation of bone density.Division of Immunology and
Osteoprotegerin can inhibit TRAIL-mediated apoptosisCancer Research Laboratory
in vitro, but its functional relationship with TRAIL in vivoUniversity of California, Berkeley
is not clear. Inmice, there is only one full-length receptor,469 Life Sciences Addition
TRAIL-R (mDR5, mTRAILR2, and mKILLER), which isBerkeley, California 94720
equally homologous to human DR4 and DR5 (Ashkenazi2School of Public Health
and Dixit, 1999; Wu et al., 1999). Like its human homo-Division of Infectious Disease
logs, this receptor is capable of signaling apoptosis inUniversity of California, Berkeley
transformed cells after either overexpression or ligationBerkeley, California 94720
by TRAIL. Two murine decoy receptors (mDcTRAILR1
and mDcTRAILR2) have also been recently reported
(Schneider et al., 2003). They lack a death domain andSummary
do not induce apoptosis in sensitive cells.
The ability to preferentially signal apoptosis in trans-TRAIL receptor (TRAIL-R) signaling has been impli-
formed cells has led to numerous studies of the mecha-cated in inducing apoptosis in tumor cells, but little is
nism of TRAIL-R signaling. We and others have shownunderstood about its physiological function. Here, we
that TRAIL-R induces apoptosis in a FADD-dependentreport the generation and characterization of TRAIL-
manner (Bodmer et al., 2000; Kischkel et al., 2000; KuangR/ mice, which develop normal lymphocyte popula-
et al., 2000; Sprick et al., 2000). Similar to Fas, onlytions but possess enhanced innate immune responses.
FADD and caspase-8 were found in the TRAIL-R signal-TRAIL-R/mice exhibited increased clearance of mu-
ing complex in these studies. In contrast, others haverine cytomegalovirus that correlated with increased
reported the recruitment of TRADDandRIP to the signal-levels of IL-12, IFN-, and IFN-. Stimulation ofmacro-
ing complex and showed that TRAIL-R, like TNF-RI, canphages with Mycobacterium and Toll-like receptor
activate NF-B and JNK (Hu et al., 1999; Lin et al., 2000;(TLR)-2, -3, and -4, but not TLR9, ligands resulted in
Muhlenbeck et al., 1998). These discrepancies couldhigh levels of TRAIL upregulation and enhanced cyto-
be due to differences in cell lines or cell type-specifickine production in TRAIL-R/ cells. The immediate-
signaling. However, the similarity to TNF receptor signal-early TLR signaling events in TRAIL-R/macrophages
ing has led to speculation that sensitivity to TRAIL in-and dendritic cells are normal, but IB- homeostatic
duced apoptosis may be regulated by expression ofregulation and NF-B activity at later time points is
antiapoptotic factors downstream of NF-B or by moreperturbed. These data suggest that TRAIL-R nega-
proximal factors such as c-FLIP, which inhibits cas-tively regulates innate immune responses.
pase-8 activation. In addition, mitochondrial factors
such as SMAC/Diablo have been implicated in regulat-Introduction
ing TRAIL-R-induced apoptosis (Deng et al., 2002). In-
deed, it may be a combination of different cytoplasmic
TRAIL (tumor necrosis factor-related apoptosis-induc-
factors that regulates sensitivity to TRAIL-R-induced
ing ligand), also known as Apo2L, was originally identi-
apoptosis.
fied through its homology to TNF (tumor necrosis factor), Although the ability to induce apoptosis in trans-
FasL, andothermembers of theTNF superfamily (Locks- formed cells is well established, the role of TRAIL and
ley et al., 2001; Nagata, 1999;Wiley et al., 1995). Addition its receptor(s) in normal mammalian physiology is not
of TRAIL induces apoptosis of many tumor cell lines understood. TRAIL has been shown to be expressed on
but, interestingly, has no apoptotic effect on most non- the surface of natural killer (NK) and T cells, macro-
transformed cells (Takeda et al., 2002; Walczak et al., phages, and dendritic cells in an activation-dependent
1999). In humans, four members of the TNF receptor manner (Almasan and Ashkenazi, 2003; Halaas et al.,
superfamily can bind TRAIL: TRAIL-R1 (DR4), TRAIL-R2 2000; Kayagaki et al., 1999; Sato et al., 2001); however,
(DR5), TRAIL-R3 (DcR1, TRID), and TRAIL-R4 (DcR2, its function remains unclear. Cells normally resistant to
TRUNDD). TRAIL-R1 and -R2 possess an intracellular TRAIL-induced apoptosis can become sensitive after
tail containing a conserved motif known as the death viral infection (Clarke et al., 2000; Lum et al., 2001; Sato
domain. As in TNF-RI and Fas, this domain allows inter- et al., 2001), and treatment of mice with neutralizing
action with the downstream adaptor protein(s) to initiate anti-TRAIL antibodies enhances their sensitivity to en-
apoptotic signals (Ashkenazi and Dixit, 1999). In con- cephalomyocarditis virus (EMCV). TRAIL-deficient ani-
trast, TRAIL-R4 possesses a truncated cytoplasmic tail mals display increased susceptibility to tumor metasta-
sis (Cretney et al., 2002) and autoimmune disease
progression (Lamhamedi-Cherradi et al., 2003) as well*Correspondence: winoto@berkeley.edu
3These authors contributed equally to this work. as defects in negative selection, although this latter find-
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ing is controversial (Cretney et al., 2003). These data introducing a frame shift and an early stop codon within
exon 7 (Figure 1E). The resulting predicted protein con-suggest that TRAIL may play roles in tumor surveillance,
regulation of autoimmunity, and T cell development. tains most of the extracellular domain of the TRAIL-R
but lacks a transmembrane domain or any of the cyto-We have now generated a mouse line deficient for the
TRAIL receptor. These mice appear to develop normally plasmic tail. To determine if a stable protein could be
encoded by this mutant sequence, constructs con-with an intact immune system. In contrast to one study
using TRAIL/ mice (Lamhamedi-Cherradi et al., 2003) taining the coding region from either the wild-type or
mutant TRAIL-R transcripts were transfected into 293Tbut consistent with another report (Cretney et al., 2003)
using the same line of TRAIL/ mice, we found no de- cells. Consistent with the endogenous TRAIL-R tran-
script levels, Northern blot analysis showed lowermRNAfects in thymic negative selection in the absence of
TRAIL-R. To assess the role of TRAIL-R in immune re- expression of the mutant transcript in transfected cells
compared to the level of thewild-type transcript in trans-sponses, we challenged TRAIL-R/mice and cells with
a variety of pathogens, including Listeria monocyto- fected cells (Figure 1F). Western blot analysis with a
TRAIL-R-specific polyclonal antibody showed that al-genes, Salmonella typhimurium, encephalomyocarditis
virus (EMCV), Mycobacterium bovis Bacillus Calmette- though the wild-type construct produced TRAIL-R pro-
tein at the expected size, no protein was generated byGue´rin (BCG), and murine cytomegalovirus (MCMV).
TRAIL-R-deficient cells were also treated ex vivo with the mutant construct (Figure 1G). These data demon-
strated that our targeted allele is indeed a null mutation.several TLR stimuli. We found that loss of TRAIL-R does
not affect responses to some challenges but led to en- To remove neomycin from the gene locus, TRAIL-R/
mice were crossed to CMV-Cre transgenic animalshanced resistance against MCMV challenge and in-
creased cytokine production in BCG-infected macro- (Nagy et al., 1998). No differences between animals with
or without the neomycin cassette were observed, andphages. In addition, macrophages and dendritic cells
lacking TRAIL-R had increased cytokine responses after an identical mutant transcript was produced by the neo-
mycin-deleted locus (data not shown).ex vivo treatment with some TLR stimuli. These data
suggest that TRAIL-R is an important negative regulator
of the cytokine responses of the innate immune system. Normal Lymphocyte Populations and Negative
Selection in TRAIL-R/ Mice
Cells from the thymus, spleen, and lymph nodes of 5-Results
to 12-week-old TRAIL-R/ animals and their littermate
controls were isolated and analyzed by flow cytometry.Generation of TRAIL-R/ Mice
Toassess thenormal physiological function of the TRAIL Loss of TRAIL-Rdid not result in any changes of the T, B,
macrophage, dendritic, or natural killer cell populationsreceptor, TRAIL-R/ mice were generated. The knock-
out construct replaced a portion of exon 5 (containing (data not shown). TRAIL has been widely reported to
function in T cell development and T cell autoimmunitythe transmembrane domain) and exon 6with a neomycin
gene cassette (Figure 1A). Embryonic stem cells con- (Lamhamedi-Cherradi et al., 2003; Song et al., 2000).
TRAIL/ animals were reported to exhibit defective neg-taining the desired homologous recombination were
identified by Southern blot analysis using 5 and 3 ative selection by one group, and blocking TRAIL func-
tion by soluble DR5 protein was found to enhance anti-probes and were then used to generate TRAIL-R hetero-
zygous mice (Figure 1B and data not shown). TRAIL-R/ CD3 T cell proliferation (Lamhamedi-Cherradi et al.,
2003; Song et al., 2000). Detailed examination of T cellmice were crossed to C57BL/6 for several generations
and subsequently intercrossed to produce homozygous development and function in TRAIL-R/ animals re-
vealed no significant alterations in T cell proliferationanimals. TRAIL-R/ mice were born at the expected
Mendelian ratios and showed no gross developmental in the absence of TRAIL-R (Supplemental Figure S1A
available online at http://www.immunity.com/cgi/content/abnormalities (data not shown). A rabbit polyclonal anti-
body generated against a bacterially expressed GST- full/21/6/877/DC1/). Consistent with these data and in
contrast with studies using human T cells (WendlingTRAIL-R (Kuang et al., 2000) protein could detect
TRAIL-R in transiently transfected cells, but not the en- et al., 2000), semiquantitative RT-PCR analysis of anti-
CD3/CD28-treated wild-type T cells did not show anydogenous protein (data not shown), presumably be-
cause of extremely low levels of endogenous TRAIL-R. significant increase in TRAILor TRAIL-R transcript levels
after stimulation (Supplemental Figure S1B). To deter-Therefore, RT-PCR analysis was performed to deter-
mine if the TRAIL-R was indeed absent in TRAIL-R/ mine if superantigen-induced negative selection was
defective in our TRAIL-R/ animals, we backcrossedmice. Analysis of transcripts from multiple tissues using
oligonucleotides spanning the region between exons 4 the TRAIL-R null allele onto the Balb/c background for
four generations and examined mammary tumor virusand 6 showed a band in TRAIL-R wild-type, but not
knockout, animals (Figure 1C). To further ensure we did (Mtv)-induced negative selection. Balb/c strain of mice
are I-Ed and carry Mtv-9, which encodes an endogenousnot have a truncated but functional transcript, we de-
signed primers to amplify the entire TRAIL-R transcript. superantigen capable of deleting V3-, V5-, and V11-
expressing T cells during negative selection (TomonariRT-PCR analysis with these TRAIL-R-specific oligonu-
cleotides showed a truncated transcript in all tissues et al., 1993; Woodland et al., 1991a, 1991b). No differ-
ences were seen in the decrease of the frequencies ofexamined, including heart, kidney, and thymus (Figure
1D). Cloning and sequencing of this transcript indicated V5andV11after selection (betweenDP [CD4CD8]
and SP [CD4CD8 or CD4CD8] cells) betweenthat themutation in the TRAIL-R locus resulted in mRNA
splicing from exon 3 to exon 7, skipping exon 4 and TRAIL-R/ animals and their littermate controls (Sup-
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Figure 1. Targeted Disruption of the Mouse TRAIL Receptor Gene Locus
(A) A schematic map of the TRAIL-R genomic locus (top) and the targeting vector (bottom). The neo cassette replaces a portion of the
transmembrane domain and all of exon 6. The 5 Southern blot probe (1 kb XbaI fragment) is indicated.
(B) Confirmation of TRAIL-R locus targeting by Southern blot analysis of the transfected embryonic stem (ES) cells. Genomic DNA from ES
cells was digested with BamHI, separated by electrophoresis, and hybridized with the radiolabeled 5 probe shown in (A). Southern blot
analysis detected a single 6.6 kb band for the wild-type allele and a 11 kb band for the knockout allele.
(C) PCR amplification of the thymus, spleen, lymph nodes, heart, lung, kidney, and brain TRAIL-R mRNAs from TRAIL-R/ and TRAIL-R/
mice was done using primers spanning exons 4 to 6 and as described in the Experimental Procedures.
(D) PCR amplification of full-length TRAIL-R transcript from heart, kidney, and thymus mRNAs from TRAIL-R/ and TRAIL-R/ mice was
done as described in the Experimental Procedures.
(E) The TRAIL-R transcript from knockout mice was cloned and sequenced. Shown here is the abnormal junction between the 3rd and 7th
exons formed in the TRAIL-R/ heart mRNA, the normal TRAIL-R reading frame, and the predicted truncated protein sequence (the asterisk
denotes the termination codon).
(F) Wild-type and mutant transcripts were cloned into the pCI expression vector and transfected into 293T cells. Northern blot analysis (F)
showed a truncated TRAIL-R transcript from the knockout transcript construct.
(G) Western blot analysis showed normal TRAIL-R protein from the wild-type construct but no protein from the knockout construct.
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Figure 2. MCMV-Infected TRAIL-R/ Ani-
mals Have Decreased Splenic Viral Titers
TRAIL-R/ (/) animals and wild-type (wt)
littermates were infected with 3  105 plaque
forming units (pfu) MCMV via the intraperito-
neal (i.p.) route.
(A) Viral titers in the liver and spleen were
determined at days 3 and 5 post infection.
pfu values are given per 100mgorganweight.
Each time point represents six animals per
genotype. The experiment has been repeated
three times with similar results.
(B) NK cell lytic activity and IFN- production
is unaffected by TRAIL-R deficiency. Left:
TRAIL-R/ andwild-type littermateswere in-
jected with MCMV via the i.p. route, and NK
cell lytic activity was assayed 24 hr later
against 51Cr labeled YAC-1 targets. The x axis
corresponds to decreasing ratios of effector
to target cells (E:T). Right: Splenocytes from
TRAIL-R/ andwild-type littermates were in-
cubated overnightwith increasing concentra-
tions of IL-12 and then stained for DX5 and
intracellular IFN-.
(C) At 24 hr after MCMV infection, the activa-
tion status as determined by CD69 expres-
sion and percent IFN- of NK cells were de-
termined. (n  4 of each genotype, the
experiment has been repeated with similar
results.) p is the significance from a Student’s
t test (values 	0.05 are considered signif-
icant).
plemental Figure S1C). These data argue against an viral titers were observed as early as 3 days postinfec-
tion with up to a 40-fold difference between TRAIL-R/essential role for TRAIL-R signaling in T cell development.
animals and their littermate controls (Figure 2A). Liver
and lung viral titers were not significantly different be-TRAIL-R/ Mice Exhibit
Enhanced Responses to MCMV tween TRAIL-R-deficient and wild-type animals (Figure
2A and data not shown).The lack of defects in naive TRAIL-R-deficient animals
prompted us to examine the response of these animals It has been shown previously that control of viral titers
in the spleen is dependent on NK cell lytic activity (Tayto a variety of pathogen challenges. No difference in
survival between TRAIL-R/ mice and their wild-type and Welsh, 1997). Similar cell numbers of NK (and NKT)
cells were present in wild-type and TRAIL-R/ spleenslittermate controls was observed after Salmonella typhi-
murium infection; bacterial titers in the liver and spleen after MCMV infection (data not shown). The lytic activity
of NKcells lacking the TRAIL-Rwas examined in animalsafter Listeria monocytogenes infection were also similar
between TRAIL-R/ animals and wild-type littermates primed with an intraperitoneal injection of poly (I:C). The
NK cells from TRAIL-R knockout animals and control(Supplemental Figures S2A and S2B). After encephalo-
myocarditis virus (EMCV) infection, TRAIL-R-deficient animals had identical lytic activity against chromium
labeled YAC-1 target cells (data not shown). Becauseanimals displayed a slightly enhanced survival rate com-
pared to littermate animals. This increased survival was poly (I:C) provides a very strong activating signal that
might mask subtle differences, we also examined NKnot observed with a 10-fold higher viral dose (Supple-
mental Figure S2C and data not shown). cells from TRAIL-R/ and wild-type littermate animals
infected with MCMV. The lytic activity of these splenicTRAIL-R/ animals and wild-type littermates in the
B6 background were then infected with murine cyto- NK cells was also similar between knockout and wild-
type animals 36 hr postinfection (Figure 2B, left). Thesemegalovirus (MCMV) (Smith strain) and viral titers were
determined for the lungs, spleens, and livers. TRAIL-R- data indicate that TRAIL R/ NK cells do not have an
inherently higher lytic activity than TRAIL-R wild-typedeficient animals had lower viral titers in their spleens
compared to control animals (Figure 2A). Differences in NK cells. We next assayed NK cells for their ability to
TRAIL Receptor and Innate Immunity
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produce IFN-. We isolated splenocytes and treated infection. Cells were then cultured for 24 hr and IL-12
levels in the culture medium assayed by ELISA. Consis-them with either IL-12 or antibodies to NK1.1 for 24 hr.
NK cells were stained for DX5 and intracellular IFN-. tent with our serum IL-12 data, dendritic cells from
TRAIL-R-deficient animals produced 8-fold more IL-12No difference in IFN--producing NK cells was observed
between wild-type and TRAIL-R/ mice after IL-12 and than cells from control animals (Figure 3B). Therefore,
enhanced cytokine production by dendritic cells likelyanti-NK1.1 treatment (Figure 2B, right, and data not
shown). Interestingly, there was a slight increase in accounts for the elevated IL-12 in the serum of knock-
out animals.CD69 NK cells directly ex vivo from MCMV-infected
animals (Figure 2C), suggesting that although their lytic In addition to IL-12, IFN-
 and IFN- are induced early
during viral infection and contribute to protectionactivity appeared to be normal, NK cells fromTRAIL-R/
mice were slightly more activated. against MCMV (Biron, 1999; Biron et al., 1999; Dalod et
al., 2003; Orange and Biron, 1996a, 1996b). DetectionIn addition to NK cells, dendritic cells are critical for
the development and maintenance of the early immune of serum IFN-
 by ELISA resulted in values close to the
limit of detection of the assay. Therefore, we assessedresponse to MCMV (Dalod et al., 2003). The composition
of splenic CD11c/CD8, CD11c/CD11b, and CD11c/ type I interferon levels by quantitative RT-PCR at 4 and
8 hr post-MCMV infection. We found elevated levelsCD11b/CD4 dendritic cells (Kamath et al., 2000) after
MCMV infection was unaltered by TRAIL-R deficiency of IFN-
 (Figure 3C) in the spleen of TRAIL-R/ mice
compared to wild-type littermates (the IFN-
 level in the(Supplemental Figure S3 and data not shown). The Perth
strain of MCMV was shown recently to cause functional liver was below detection). IFN- levels in the liver and
spleen showed the same trend although the differenceparalysis of dendritic cells and immune suppression (An-
drews et al., 2001) as evidenced by downregulation of between TRAIL-R-deficient and wild-type mice was not
as dramatic (Figure 3C). These data suggest thatclass II MHC, CD80, and CD40 levels on activated den-
dritic cells 4 days postinfection. To determine if the en- TRAIL-R signaling negatively regulates in vivo produc-
tion of cytokines by innate immune cells. The increasedhanced MCMV immunity in TRAIL-R/ mice could be
attributed to alterations in the general activation state levels of IL-12 by dendritic cells likely leads to a greater
number of IFN--secreting NK cells, resulting in the en-of the dendritic cells, we examined surface markers on
CD11c/CD3 spleen cells at days 1, 3, 5, and 7 post- hanced clearance of MCMV from the spleens of TRAIL-
R-deficient animals.MCMV (Smith strain) infection. No difference in the acti-
vation status of dendritic cells during this period was
seen between TRAIL-R/ and wild-type littermate mice Stimulation through Some, but Not All, TLRs Leads
as assessed by class II MHC I-Ab, CD80, CD86, and to Increased TRAIL Levels
CD40 expression (Supplemental Figure S3 and data not To explore the mechanism of inhibition of cytokine pro-
shown). Expression of activation markers increased on duction by TRAIL-R in vitro, we first examined the ex-
all subsets of dendritic cells from wild-type and knock- pression levels of TRAIL and TRAIL-R in stimulated in-
outmice betweendays 0 and 1 after infection. Activation nate immune cells. Other groups (Griffith et al., 1999;
markers decreased between days 1 and 3 post infection Halaas et al., 2000) have established that human mono-
and remained unchanged through day 7, except for a cytes andmacrophages upregulate TRAIL after stimula-
slight downregulation of CD40 between days 5 and 7 in tion with E. coli-derived lipopolysaccharide (LPS). We
animals of both genotype (Supplemental Figure S3 and examined TRAIL and TRAIL-R transcript levels in thio-
data not shown). These data suggest that TRAIL-R loss glycolate-elicited murine peritoneal macrophages after
has no effect on the expression of cell surfacemolecules stimulation with E. coli LPS. In contrast to anti-CD3/
on dendritic cells or the composition of dendritic cells CD28 stimulated T cells, mouse macrophages signifi-
during an MCMV infection. cantly upregulated TRAIL transcripts after activation,
starting at 3 to 4 hr poststimulation (Figure 4A and Sup-
plemental Figure S4). Exposure of these macrophagesMCMV-Infected TRAIL-R/ Mice Exhibit Increased
Cytokine Production to the Mycobacterium bovis Bacillus Calmette-Gue´rin
(BCG) also led to upregulation of TRAIL transcripts butCytokine secretion by a variety of cells after viral infec-
tion is critical in the establishment of an antiviral state. with slightly delayed kinetics compared to LPS stimula-
tion (Figure 4A). In contrast, the levels of TRAIL-R didIn the context of an MCMV infection, early IL-12 produc-
tion by dendritic cells induces NK cell IFN- production not change significantly with either stimulation.
The Toll-like receptors (TLRs) recognize conservedwhose levels in the serum peak 36 hr postinfection
(Biron, 1999; Biron et al., 1999; Dalod et al., 2003; Orange motifs found on many microorganisms and represent
the primary means by which macrophages, dendriticand Biron, 1996a, 1996b). NK cells are a major producer
of IFN-, which is necessary in the liver for MCMV immu- cells, and other cells of the innate immunesystem recog-
nize pathogens. Since LPS and BCG are known to acti-nity. Examination of serum cytokine levels at 24 hr post-
infection revealed a nearly 10-fold increase in levels of vate macrophages through TLR4 and 2, respectively
(Heldwein et al., 2003; Poltorak et al., 1998), we exam-the IL-12 p40 subunit in TRAIL-R/ animals compared
to wild-type littermates (Figure 3A). Furthermore, serum ined changes in TRAIL expression in macrophages in
response to other TLR stimuli (Takeda et al., 2003). Bylevels of IFN- at 36 hr postinfection were greatly ele-
vated in TRAIL-R/ animals compared to wild-type lit- using quantitative PCR, we confirmed the kinetics of
TRAIL upregulation at 4 hr post-LPS treatment (Figuretermates (Figure 3A). To examine directly the cells that
produce IL-12, CD11c dendritic cells were isolated 4B). Other stimuli like lipoteichoic acid (LTA, TLR2 li-
gand) and poly (I:C) (TLR3 ligand) also upregulatedfrom the spleens of MCMV-infected animals 24 hr post-
Immunity
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Figure 3. MCMV-Infected TRAIL-R/ Ani-
mals Exhibit Increased Cytokine Levels
(A) Serum IL-12(p40) levels weremeasured by
ELISA 24 hr post-MCMV infection, and IFN-
levels were measured 36 hr post-MCMV in-
fection.
(B) Dendritic cells from MCMV-infected
TRAIL-R/ animals display increased IL-12
production. Splenocytes from MCMV-infected
animals were isolated 24 hr postinfection and
sorted for CD11c expression. Cells were
plated and cultured for 24 hr. IL-12(p40) in
the culture medium was measured by ELISA.
(C) MCMV-infected TRAIL-R/ animals ex-
hibit increased levels of type I interferons in
their spleens and livers. Quantitative RT-PCR
(done in triplicate for each sample) was per-
formed on RNA from the spleens and livers
ofTRAIL-R/ animals andwild-type littermates
4 and 8 hr postinfection (for each genotype,
n  2 for the 4 hr time point and n  3 for the 8 hr time point). The experiments have been repeated twice with similar results. The levels of
interferon-
 in the liver were too low to be detected. The interferon expression was normalized to -actin.
TRAIL with similar kinetics. Interestingly, TRAIL tran- Enhanced Cytokine Production in TRAIL-R/ Cells
after Stimulation with TLR Ligands or BCGscription after stimulation with nonmethylated CpGDNA
(TLR9 ligand)was not as strong in comparisonwith other We next examined the effects of TRAIL-R deficiency on
the macrophage response to LPS or BCG stimulation.ligands (Figure 4B). TRAIL-R levels were not significantly
changed after any of these treatments (Figure 4C and After exposure to LPS or BCG, macrophages secrete
TNF
. We examined production of TNF
 by intracellulardata not shown).
Figure 4. Macrophages Upregulate TRAIL Transcripts in Response to Stimulation with E. coli LPS, Bacillus Calmette-Gue´rin (BCG), LTA, and
poly (I:C)
(A) Semiquantitative RT-PCR was used to determine the levels of TRAIL and TRAIL-R transcripts in wild-type thioglycolate elicited peritoneal
macrophages after stimulation with E. coli-derived LPS or live BCG at the indicated time points. RT: no reverse transcriptase.
(B) Quantitative RT-PCR analysis of TRAIL transcripts after different TLR stimuli. TRAIL is strongly upregulated by LPS, LTA, and poly(I-C),
but not CpG. Normalized TRAIL Expression is the ratio of TRAIL to -actin transcripts.
(C) Quantitative RT-PCR analysis of TRAIL-R transcripts after LPS stimulation. TRAIL-R remains unchanged after LPS treatment. TRAIL-R
expression was normalized to -actin transcripts.
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Figure 5. TRAIL-R/ Macrophages Display Increased TNF
 Production in Response to LPS and BCG and Abnormal Activation in Response
to BCG Infection
(A) Thioglycolate elicited peritoneal macrophages from TRAIL-R/ animals and wild-type littermates were stimulated with live BCG and stained
for intracellular TNF
 (12 hr) and surface F4/80 and Db (24 hr). The surface marker staining profiles at 6 hr post infection are equivalent to
noninfected controls and are shown here for comparison (left). Cells were also stained for intracellular TNF
 after treatment with E. coli LPS.
The experiments were done three times with similar results.
(B) Thioglycolate elicited peritoneal macrophages from TRAIL-R/ (/) and / or / (wt) littermates were treated with titrated doses of
E. coli or Salmonella LPS. IL-12(p40) production was measured 24 hr posttreatment. TNF
 was measured 6 hr posttreatment by ELISA. Data
is representative of at least three different experiments.
cytokine staining in wild-type and TRAIL-R-deficient (a TLR2 ligand), lipoteichoic acid (LTA), nonmethylated
CpG DNA, and poly (I:C). In response to both forms ofcells. Intracellular cytokine staining ofmacrophages iso-
lated from TRAIL-R/ animals consistently revealed LPS, TRAIL-R/ macrophages produced greater TNF

and IL-12 than wild-type macrophages (Figure 5B). Thehigher numbers of TNF
-producing cells compared to
macrophages isolated from wild-type littermates after same was true after stimulation with zymosan (Figure
6A). TRAIL-R/ macrophages also produced more IL-stimulation with BCG or LPS (Figure 5A, right two pan-
els). In addition to TNF
 production, BCG, but not LPS, 12 in response to poly (I:C) and LTA (Figure 6A). Interest-
ingly, no difference in IL-12 production was observedcauses downregulation of the surface expression of the
F4/80 macrophage specific antigen and class I major in response to CpG DNA (Figure 6A). This is consistent
with lower levels of TRAIL upregulation byCpGDNA (seehistocompatibility complex (MHC) (Ezekowitz and Gor-
don, 1982). Downregulation of F4/80 and Db class I MHC Figure 4B) and suggests that activation of the TRAIL/
TRAIL-R pathway in macrophages provides negativecell surface expressionwas less pronounced in TRAIL-R/
cells after BCG exposure (Figure 5A, left two panels). feedback regulation of signaling through TLR2, TLR3,
and TLR4, but not TLR9.The function of F4/80 remains unclear, but studies using
blocking antibodies suggest F4/80 enhances macro- To determine if the effects of TRAIL-R deficiency on
cytokine production extended to other cells of the innatephage cytokine secretion (Warschkau and Kiderlen,
1999), and its downregulation may be a mechanism for immune system, we also examined the response of
TRAIL-R/ and wild-type bone marrow-derived den-shutting off cytokine production. Therefore, increased
F4/80 expression in TRAIL-R/ cells is consistent with dritic cells to E. coli derived LPS. Similar to TRAIL-R/
macrophages, dendritic cells lacking TRAIL-R had ele-increased TNF
 production. The cause of Db downregu-
lation by BCG is also unclear but may represent an vated levels of cytokine production (Figure 6B). Stimula-
tion of Flt3L expanded splenic dendritic cells with LPSimmunosuppressive effect of BCG. Taken together,
these data suggest that TRAIL-R is a regulator of TNF
 also revealed increased IL-12 production (data not
shown). These data indicate that TRAIL-R regulation ofproduction as well as the overall macrophage activa-
tion state. cytokine production after TLR stimulation is important
in both macrophages and dendritic cells.To examine the cytokine response to other TLR li-
gands (Takeda et al., 2003), macrophages isolated from To examine the effect of exogenously added TRAIL
on macrophage cytokine secretion, we stimulated boneTRAIL-R/ animals and wild-type littermates were
treated with LPS from E. coli and Salmonella, zymosan marrow and peritoneal macrophages with LPS in the
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Figure 6. Enhanced Cytokine Production by TRAIL-R/ Cells in Response to Different TLR Stimuli
(A) Thioglycolate elicited peritoneal macrophages from TRAIL-R/ (/) and / or / (wt) littermates were treated with titrated doses of
various TLR specific stimulants. IL-12(p40) production was measured 24 hr posttreatment. TNF
 was measured 6 hr posttreatment.
(B) Bone marrow derived dendritic cells from TRAIL-R/ and wild-type littermate controls were treated with serial dilutions of LPS for 6 hr
and IL-12 production was measured by ELISA.
(C) TRAIL-R/ bone marrow-derived macrophages were retrovirally transduced with virus encoding for TRAIL-R. Cells were stimulated with
increasing concentrations of LPS in the presence or absence of TRAIL (125 ng/ml).
presence or absence of TRAIL and measured IL-12 and vation of MAP kinases as well as NF-B. We examined
these pathways after LPS stimulation to determine ifTNF
 by ELISA. We observed no difference in IL-12
secretion and only a modest decrease in TNF
 produc- TRAIL-R deficiency affected TLR downstream signaling
events. We first assessed the activation of MAP kinasestion (data not shown). One possible explanation for this
finding is that TRAIL-R might be present at such a low by determining the phosphorylation status of ERK1/2,
p38, and JNK. All of themwere phosphorylated at similarlevel that the amount of endogenously produced TRAIL
after LPS stimulation is saturating. Thus, adding more levels and with similar kinetics in TRAIL-R/ and wild-
type macrophages (Figure 7A and Supplemental FigureTRAIL would not enhance the endogenous TRAIL-R sig-
naling. To overcome this possible problem, we retrovi- S4). To examine NF-B activation, we analyzed the lev-
els of IB-
, which sequesters NF-B in the cytoplasmrally infected TRAIL-R/ bone marrow-derived macro-
phageswith anMSCVbasedvirus encoding theTRAIL-R in a transcriptionally inactive complex. Activation of this
pathway leads to phosphorylation and degradation ofcDNA. This approach is known to modestly increase the
amount of TRAIL-R and accentuate its signal transduc- IB-
, permitting the translocation of NF-B to the nu-
cleus and activation of its transcriptional targets. Ho-tion pathway (data not shown). As predicted, IL-12 pro-
duction after LPS treatment was decreased by the addi- meostatic regulation of NF-B occurs through the syn-
thesis of new IB-
, which sequesters NF-B back intotion of TRAIL in the TRAIL-R reconstituted cells (Figure
6C). No apoptosis was detected in these cells (data the cytosol (Hoffmann et al., 2002).Western blot analysis
of IB-
 showed that macrophages from TRAIL-R/not shown). This data further confirmed the notion that
TRAIL-R signaling negatively regulates macrophage cy- animals and wild-type littermates displayed similar ki-
netics of IB-
 phosphorylation and degradation imme-tokine production.
diately after LPS stimulation, indicating that TRAIL-R
deficiency did not affect the initial activation of NF-BTRAIL-R Regulates the Late Phase
of TLR Signaling (Figure 7A). However, at later time points (4 and 8 hr
post stimulation), when IB-
 protein was reexpressedRecognition of pathogens by Toll-like receptors leads
to a rapid defensive response (Barton and Medzhitov, in the wild-type cells, it could not be detected in
TRAIL-R/ cells (Figure 7A). These data are consistent2003a, 2003b). This response is mediated through acti-
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Figure 7. Biochemical Analysis of LPS-Stimulated Macrophages and Dendritic Cells
(A) Bone marrow-derived macrophages (top) and dendritic cells (bottom) from TRAIL-R/ and wild-type littermate controls were treated with
1 g/ml LPS (macrophages) or 100 ng/ml LPS (dendritic cells) for the indicated time points. Cell lysates were used for Western blot analysis
with antibodies specific for total (IB-
) or phosphorylated IB-
 (P-IB-
), phosphorylated JNK (P-JNK), or phosphorylated p38 (P-p38). As
a loading control, antibodies for total p38 (macrophage) or total ERK1/2 (DC) were used. The experiments have been done more than three
times with similar results.
(B) Bone marrow-derived macrophages from TRAIL-R/ and wild-type littermate controls were treated with 50ng/ml LPS and nuclear extracts
were generated and analyzed by EMSA for NFB activity as described in the materials and methods. EMSA for the GT box was performed
as a loading control.
(C) LPS pulse experiments. Bone marrow macrophages from TRAIL-R/ and wild-type littermate controls were treated for 1 hr with LPS,
washed four times with PBS and incubated for the indicated times with media without LPS. Nuclear extracts were generated and analyzed
by EMSA for NF-B activity. The experiments in (B) and (C) have been done at least twice with similar results. The numbers below the NF-
B gel shift represent phosphoimager values (106) of the NF-B binding activities after normalization to the corresponding GT box values.
with the delayed time course of TRAIL upregulation (4 hr (data not shown). Thus, TRAIL-R signaling most likely
regulates IB-
 degradation or stability, but not the tran-post LPS stimulation, see above) and suggest that
TRAIL-R primarily impacts late signaling events down- scription of IB-
 after NF-B activation.
To assess the differences in NF-B transcriptionalstreamof Toll-like receptors. Similar findingswere found
in bone marrow-derived dendritic cells from TRAIL-R/ activity in TRAIL-R wild-type and knockout macro-
phages, we performed gel shift assays by using the NF-and wild-type littermates treated with LPS (Figure 7A).
No difference in IB-
 protein levels was observed be- B consensus sequence. As a control, the same nuclear
extracts were incubated with GT box oligonucleotides,tween wild-type and knockout macrophages after TNF

stimulation (Supplemental Figure S4), indicating that the which detect members of the ubiquitously expressed
Sp1 transcription factors (Kingsley and Winoto, 1992).loss of IB-
 is specific to TLR stimuli. Quantitative PCR
analysis of IB-
 transcript levels in macrophages at Bone marrow macrophages were stimulated with LPS
and nuclear extracts were made. Early NF-B activitiesdifferent time points after LPS stimulation showed simi-
lar expression levels in wild-type and TRAIL-R/ cells were similar between TRAIL-R/ and TRAIL-R/ mac-
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rophages (data not shown). At later time points a consis- tively regulating T cell proliferation with consequences
for the development of autoimmune diseases (Hilliardtent, albeit modest increase in DNA binding by NF-B
et al., 2001; Song et al., 2000). We have been unable towas observed in TRAIL-R/ macrophages (Figure 7B).
show significant alterations in T cell proliferation afterOthers have previously reported that NF-B binding ac-
the addition of exogenous recombinant TRAIL (data nottivities in continuously TNF-
 treated IB-
-deficient
shown). Furthermore, TRAIL-R loss in T cells does notcells were barely discernable but the increase was evi-
significantly affect proliferation following TCR/CD28 li-dent in cells treated with a brief pulse of stimulus (Hoff-
gation.mann et al., 2002). We performed a similar experiment
The normal lymphocyte homeostasis observed in ourand stimulated wild-type and TRAIL-R/ macrophages
TRAIL-R-deficient animals led us to examine TRAIL-Rfor 1 hr with LPS. The cells were washed and assayed
function in the context of an immune response to severalat various time points afterward. Quantitative RT-PCR
bacterial and viral pathogens. Although TRAIL-R lossexperiment showed that TRAIL is upregulated 2 hr after
had no effect on S. typhimurium infection, it did have awashing (Supplemental Figure S4). As shown in Figure
slight protective effect in the context of EMCV infection7C, TRAIL-R/macrophages exhibited amore dramatic
and significantly enhanced clearance of MCMV fromincrease of NF-B binding activities, especially at 2 hr
the spleen. The mechanism of protection from EMCVpost wash.
is unclear but it likely does not involve virally induced
apoptosis of infected cells or viral reproduction andDiscussion
spread to the heart, one of the main target organs (data
not shown). In response to MCMV infection, TRAIL-R/The vast majority of studies of TRAIL-R function have
animals had enhanced antiviral responses, which led toexamined its abilities to induce apoptosis preferentially
lower viral titers in the spleens of knockout animals. Noin transformed cells. More recently, studies have exam-
increase in lytic activity was found in the TRAIL-R/ NKined the expression of TRAIL and its receptors after
cells, although slightly more TRAIL-R/ splenic NK cellsimmune cell activating stimuli as well as the role of
expressed the CD69 activationmarker. Analysis of cyto-TRAIL-R in autoimmunity and defense against viral in-
kine production in knockout animals revealed elevatedfections. Studies with TRAIL-deficient mice have also
levels of IL-12 and IFN- in the serum compared tosuggested a role for TRAIL-R signaling in thymic nega-
control animals. In addition, knockout animals displayedtive selection, although this conclusion is controversial
higher levels of type I interferons in the spleen at early(Cretney et al., 2003; Lamhamedi-Cherradi et al., 2003).
time points after MCMV challenge. We also examinedOur data now demonstrate the importance of TRAIL-R
splenic dendritic cells, which have been identified assignaling in the initial cytokine responses of the immune
the major producer of IL-12 during an MCMV infectionsystem to pathogen challenge.
(Dalod et al., 2002) and are important for the initiationSimilar to TRAIL/ mice, examination of unchal-
of NK cell antiviral responses. While surface markers forlengedTRAIL-R/micedid not reveal any abnormalities
dendritic cell activation were similar between TRAIL-R/in their resting immune cell populations, indicating that
and wild-type littermates during the course of an MCMV
TRAIL-R does not play an essential, nonredundant role
infection, dendritic cells derived from MCMV-infected
in the development of the immune system. In addition,
TRAIL-R/ animals showed elevated production of IL-
lymphocyte homeostasis appears unperturbed, even in
12 compared to dendritic cells from wild-type lit-
aged animals. It is interesting to note that unlike muta- termates. This increased IL-12 could result in increased
tions in the related family member Fas, TRAIL-R defi- NK cell lytic activities. Although we did not see an obvi-
ciency does not lead to lymphoproliferative conditions ous difference in NK activities and activation in vitro,
or the development of an abnormal B220/Thy1 T cell others have shown that in vivo NK cell lytic activities
population. It has been shown previously that loss of are hard to measure in vitro (Dokun et al., 2001). In these
TNF receptor in the lpr background can enhance the studies, the activities and proliferation state of NK cells
lymphoproliferative phenotype even though TNF-RI/ between the resistant Ly49H strain (e.g., C57Bl/6) and
animals display normal peripheral deletion (Zhou et al., the sensitive Ly49H strain (e.g. Balb/c) were compara-
1996). It remains to be seen whether compound defi- ble although MCMV titers were already severely attenu-
ciency in Fas and TRAIL-R would have any synergistic ated at day 2 of infection in Ly49H mice. Thus, the
effects on lymphocyte homeostasis. decrease of MCMV spleen titer in TRAIL-R/mice could
Examination of the lymphocyte populations from be due to increased NK lytic activities in vivo although
TRAIL-R-deficient animals has revealed some differ- type I interferons might also contribute to the acceler-
ences with previous studies by using either TRAIL-defi- ated clearance.
cient animals or TRAIL-blocking antibodies. It has been While infection of TRAIL-R/micewith Listeria mono-
reported that TRAIL deficiency leads to defects in nega- cytogenes bacteria did not reveal differences in organ
tive selection, including defective endogenous superan- bacterial load, others, using TRAIL/ mice in the Balb/c
tigen deletion of certain thymocyte subsets (Lamhamedi- background, observed faster clearance and increased
Cherradi et al., 2003). However, our TRAIL-R/ animals survival after Listeria challenge (Zheng et al., 2004). The
displayed no such alterations when compared to wild- difference between these studies may be attributable
type littermates using the same model of endogenous to the differences in challenge dose as well as differ-
superantigen deletion. This is consistent with a recent ences in the resistant C57/BL6 background versus the
study by Cretney et al. (2003) reporting normal thymic more susceptible Balb/c background. However, their
negative selection in TRAIL deficient animals. Others results are consistent with our in vitro macrophage data
and in vivo MCMV data and support a role for the TRAIL/have reported that TRAIL signaling is important in nega-
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TRAIL-R pathway in the negative regulation of innate im- prevent it from degradation. The molecular mechanism
munity. by which TRAIL-R signaling stabilizes IB-
 is not clear
Our results with TRAIL-R-deficient animals differ sig- at present. However, in somecells, FADDand caspase-8
nificantly from other studies that examined the function are recruited to the TRAIL-R signaling complex upon
of TRAIL-R signaling in T cell proliferation (Song et al., ligand stimulation, leading to caspase activation and
2000) and EMCV immunity (Hilliard et al., 2001) with apoptosis (Kischkel et al., 2000; Kuang et al., 2000;
soluble anti-TRAIL reagents. The ability of membrane Sprick et al., 2000). In macrophages and dendritic cells,
bound TRAIL to transduce signals may be one explana- caspase-8 activation does not lead to apoptosis but
tion for this discrepancy. Chou et al. (2001) have shown may result in cleavage of signaling molecules down-
that crosslinking TRAIL by using either plate bound stream from TLRs. For example, RIP1 is a mediator for
TRAIL-R or a soluble TRAIL-R can lead to increased IB phosphorylation and degradation and is a known
T cell proliferation in the presence of suboptimal TCR target of caspase-8 (Lin et al., 1999). More recently, RIP1
simulation. Signaling through membrane bound TRAIL has been shown to be an essential signaling protein
can lead to increased IFN- production in a p38- of NF-B activation after TLR3 stimulation (Barton and
dependant manner (Chou et al., 2001). These cellular Medzhitov, 2004; Meylan et al., 2004). Thus, TRAIL-R
responses to TRAIL- (and not TRAIL-R-) mediated sig- may stabilize IB and inhibit TLR signaling by inducing
naling may lead to the phenotypes associated with ex- cleavage of proteins such as RIP1.
periments using TRAIL blocking agents. In particular, it In summary, the data presented here define a role for
may explain the difference between the results of our TRAIL-R signaling independent of its ability to initiate
EMCV infection of TRAIL-R knockout animals compared apoptosis in sensitive cells. By using mice deficient for
to other studies using anti-TRAIL antibodies. It is inter- TRAIL-R,we have shown that TRAIL-R signaling contrib-
esting to speculate that in certain situations, the TRAIL utes to the negative regulation of cytokine production
decoy receptors could act as “ligands” to signal through in macrophages and dendritic cells in the context of
the membrane bound TRAIL “receptor.” both ex vivo and in vivo challenges. Furthermore, we
Macrophages and dendritic cells are the primary cells, showed that the TRAIL/TRAIL-R pathway constitutes a
which mediate innate immune responses to pathogens negative feedback loop for TLR2, TLR3, and TLR4, but
and assist in the shaping of the adaptive response. Stim- not TLR9, signaling. Further studies will be necessary
ulation of macrophages and dendritic cells derived from to elucidate the exact molecular pathway by which
TRAIL-R/ animals demonstrates that TRAIL-R signal- TRAIL-R affects cellular responses to TLR signaling.
ing negatively regulates cytokine secretion in both cell
types. In the case of macrophages treated with LPS and Experimental Procedures
other TLR stimuli and dendritic cells isolated after an
Detailed Experimental Procedures are available online as Supple-MCMV infection, TRAIL-R deficiency does not appear
mental Data at http://www.immunity.com/cgi/content/full/21/6/877/to affect other aspects of cellular activation (as assessed
DC1/.by surface activation markers) and suggests that TRAIL-R
signaling is primarily repressive for cytokine production.
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